XOMA Corporation (XOMA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Mar, 2026Executive summary
Annual meeting scheduled for May 21, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials online and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of seven director nominees for terms expiring in 2027.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Approval of amendment and restatement of the 2010 Long Term Incentive and Stock Award Plan.
Approval of the 2026 Employee Stock Purchase Plan.
Advisory vote on executive compensation (say-on-pay).
Board of directors and corporate governance
Seven director nominees listed for election, with board recommending a vote for all.
Partial view of Summaries dataset, powered by Quartr API
Latest events from XOMA Corporation
- Shareholders will vote on director elections, auditor ratification, equity plans, and executive pay.XOMA
Proxy filing30 Mar 2026 - Royalty receipts rose 68% and the portfolio doubled, fueling strong cash flow and profitability.XOMA
Q4 202518 Mar 2026 - Diversified royalty portfolio, strong cash flow, and major pipeline catalysts ahead.XOMA
Leerink Global Healthcare Conference 202611 Mar 2026 - Diversified royalty portfolio, multiple phase III catalysts, and profitability targeted by 2027.XOMA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Biotech royalty aggregator grew to 100+ assets, with strong cash flow and key 2026 milestones ahead.XOMA
Corporate presentation2 Mar 2026 - Scalable royalty aggregation model targets early-stage biotech assets for sustained growth.XOMA
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Targets early-stage biotech royalties for high-margin, long-term cash flow and disciplined growth.XOMA
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Early-stage asset focus and scalable model set to drive royalty growth and cash flow ramp.XOMA
Leerink Global Healthcare Conference 202526 Dec 2025 - Scalable royalty aggregation and disciplined capital deployment drive growth from 130+ biotech assets.XOMA
Jones Healthcare and Technology Innovation Conference 202523 Dec 2025